Author: McCreary, Erin K; Pogue, Jason M
Title: Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options Document date: 2020_3_23
ID: j0i9ozsz_45
Snippet: Patient populations who warrant therapy and the timing of initiation of therapy need to be defined. Given that disease progression can occur rapidly in stable patients and that viral loads are highest early in the infection course, the authors of this review opine that rapid initiation of therapy in high-risk populations (patients who are hospitalized or outpatients who are at high risk of complications) is rational and should be considered, idea.....
Document: Patient populations who warrant therapy and the timing of initiation of therapy need to be defined. Given that disease progression can occur rapidly in stable patients and that viral loads are highest early in the infection course, the authors of this review opine that rapid initiation of therapy in high-risk populations (patients who are hospitalized or outpatients who are at high risk of complications) is rational and should be considered, ideally in the context of a well-controlled, adequately powered trial. More important, however, this strategy is not without risk and needs to be weighed against potential adverse events (that remain poorly defined) and impending drug shortages with increases in use of these agents. To help address these concerns, careful consideration should be given to duration of therapy with many clinical trials and institutional protocols recommending 5-7 days for uncomplicated disease. Duration of therapy should be individualized to the patient and the progression of disease.
Search related documents:
Co phrase search for related documents- adverse event and careful consideration: 1
- adverse event and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- adverse event and define need: 1, 2
- adverse event and disease progression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- adverse event and high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64
- adverse event and high risk population: 1, 2
- adverse event and infection course: 1
- adverse event and institutional protocol: 1
- adverse event and patient population: 1, 2, 3, 4, 5, 6, 7, 8, 9
- adverse event and potential adverse event: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- adverse event and stable patient: 1
- adverse event and therapy duration: 1, 2, 3, 4
- adverse event and therapy initiation: 1, 2, 3
- adverse event and viral load: 1, 2, 3, 4, 5, 6
Co phrase search for related documents, hyperlinks ordered by date